Navigation Links
InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
Date:4/1/2008

p>

To access the webcast, please log on to the company's website at http://www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID #41908166. The webcast will remain available on the company's website for approximately 10 business days.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a research and development portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated product development timelines. All forward-looking statements and other information included in this press release are based on infor
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. InterMune Announces Start of Phase 1b Trial of ITMN-191
2. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
3. Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101
4. Kingfisher Announces FDA 510(k) Clearance of Breakthrough KFH Energy for Chronic Pain Sufferers
5. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
8. Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
11. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... , Oct. 20, 2014 CTI BioPharma ... it will report its third quarter 2014 financial results ... the U.S. financial markets. Following the announcement, members of ... to discuss the results and provide a general corporate ... to the event can be obtained as follows: ...
(Date:10/19/2014)... Große Pharmafirmen werden oft ... dabei ist, dass große Pharmafirmen nicht willens sind, ... Es war deshalb nicht einfach, diesen ... mehr, dass es uns gelungen ist! Wir haben ... - mit einem Vorbehalt - einige haben uns ...
(Date:10/17/2014)... , Oct. 17, 2014 With the ... Affairs function has come across several challenges in ... and managing globalization.  The ... is dedicated to providing benchmarking and best practices ... Consortium is a service composed of three stages: ...
Breaking Medicine Technology:CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2Vergleichsbericht zu Pharma-Kühlketten und CRT 2Early Key Findings from the Medical Affairs Consortium Research 2
... Inc. (Nasdaq: AUXL ) today announced that ... 31st Annual Health Care Conference during March 7-9, 2011 ... Chief Financial Officer, is scheduled to present an overview ... a.m. ET on Wednesday, March 9, 2011.   ...
... 2, 2011 Nile Therapeutics, Inc. (Nasdaq: ... novel therapeutics for heart failure patients, today announced that, ... determination from the NASDAQ Listing Qualifications Panel (the "Panel") ... for an extension to remain listed on The NASDAQ ...
Cached Medicine Technology:Auxilium Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference 2Auxilium Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference 3Nile Therapeutics Receives Positive NASDAQ Panel Decision 2Nile Therapeutics Receives Positive NASDAQ Panel Decision 3
(Date:10/20/2014)... The Advocator Group, LLC is ... Foundation for Suicide Prevention’s (AFSP) Out of the Darkness ... organization that hosts hundreds of community walks throughout the ... used to help understand and prevent suicide through not ... well. , The Advocator Group shares this passion ...
(Date:10/20/2014)... 20, 2014 Zereana Jess-Huff, a 34-year-old mother, ... 2014 on a platform to think outside the bra. She ... her position to raise awareness about women’s other lady parts. ... cancer. You say the color pink and everybody knows what ... a fact that it has not been won when it ...
(Date:10/20/2014)... Myoderm announced today the ... their CentralSource service. Matthew will play ... drug sourcing, distribution, and management service for international ... of industry experience, in both business development and ... their international success to help clients manage their ...
(Date:10/20/2014)... 2014 Final Cut Pro X Plugin developers ... Citrus theme for FCPX filmmakers . , “Fun, cool, ... the Citrus theme” Says Christina Austin, CEO of Pixel Film ... professional.” , Citrus comes with all the tools needed for ... four transitions for added style, a title screen for an ...
(Date:10/20/2014)... Maryland, USA (PRWEB) October 20, 2014 ... to track interventions? Here comes a wonderful app Metassessor ... mobile app development company helped its client “Intervention ... more efficiently. The app is designed for iOS 4.3 ... iPod touch. This app is optimized for iPhone 5. ...
Breaking Medicine News(10 mins):Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 2Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 3Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3
... BETHESDA, Md. (May 1, 2009) − Medical science took ... that, at least temporarily, perform the function of vital ... machine and renal dialysis, require the blood to be ... known as extracorporeal circulation (EC) and have provided critical ...
... in the May 1 issue of the journal SLEEP ... more likely to suffer from significant sleep disturbances at 2 ... of the study are of particular importance, as sleep disturbances ... depression in childhood. , Results indicate that infants ...
... who are wounded in combat as the result of a ... develop an abnormality known as heterotopic ossification. In this condition, ... near a fracture or other bone injury. New research conducted ... helping to pave the way for a better understanding of ...
... President pro Tem Darrell Steinberg (D-Sacramento) today announced ... Autism (ASD) & Related Disorders which will build ... the three-year California Legislative Blue Ribbon ... by Steinberg and ended in November 2008. ...
... (NYSE: BKD ) announced today that it plans to ... on Wednesday, May 6, 2009. The Company has also scheduled ... 2009 at 10:00 AM ET. The conference call can be ... 634-9069 (from outside of the U.S.) ten minutes prior to the ...
... news updates, features live, daily call-in shows hosted by world-class ... Ten Swine Flu FAQs at www.sirius.com/doctorradio , NEW ... (Nasdaq: SIRI ) has begun regular live updates ... health and medical channel powered by NYU Langone Medical Center. ...
Cached Medicine News:Health News:Chemical can reproduce complications for some patients 2Health News:Chemical can reproduce complications for some patients 3Health News:Chemical can reproduce complications for some patients 4Health News:Chemical can reproduce complications for some patients 5Health News:Maternal depression is associated with significant sleep disturbance in infants 2Health News:Injured Marines at risk for abnormal bone growth 2Health News:Steinberg Announces Senate Select Committee on Autism and Related Disorders 2Health News:Brookdale Announces First Quarter 2009 Release and Earnings Call 2Health News:Swine Flu Epidemic Reported on by Doctors on SIRIUS XM's Doctor Radio Channel 2Health News:Swine Flu Epidemic Reported on by Doctors on SIRIUS XM's Doctor Radio Channel 3Health News:Swine Flu Epidemic Reported on by Doctors on SIRIUS XM's Doctor Radio Channel 4Health News:Swine Flu Epidemic Reported on by Doctors on SIRIUS XM's Doctor Radio Channel 5Health News:Swine Flu Epidemic Reported on by Doctors on SIRIUS XM's Doctor Radio Channel 6
The Nine West Eyewear collection is positioned to present today's styles with a sharp, edgy contemporary attitude tied into a clean design element....
Inquire...
Inquire...
Inquire...
Medicine Products: